Enterosgel Tube 225 g. - Relief from IBS Symptoms: Diarrhoea, Abdominal Pain, Bloating, Urgency | Irritable Bowel Syndrome Treatment | Acute Diarrhoea Relief

Product Information

The study provides evidence that Enterosgel reduces diarrhoea duration in patients with acute diarrhoea of infectious or non-infectious aetiology. Overall, the results show that Enterosgel ® is an effective treatment and can improve quality of life for IBS-D patients, many of whom experience incapacitating symptoms. We used an official guideline to diagnose people with IBS-D, which may have stopped people with milder symptoms from being able to join the study. Information and statements about products are not intended to be used to diagnose, treat, cure, or prevent any disease or health condition.

This study aims to recruit 430 adult participants with IBS-D, from approximately 30 medical practices and outpatient clinics in the UK. If the symptoms of diarrhoea persist or are severe, it can lead to dehydration and general fatigue, so it is best to prevent this from happening in the first place. Stool samples collected at screening visit were evaluated for the presence of rotavirus, norovirus and common diarrhoea causing bacteria. It targets the cause of gastrointestinal symptoms by binding the bacterial toxins and other harmful substances and expelling them from the body via the stool. participants from the study also took part in an interactive webinar where they learnt about the study results and could ask the study team any questions.Subjects randomised to the experimental group received Enterosgel (n=51) to be taken according to instructions dependent on stool frequency and consistency and standard care, that is, oral rehydration solution (ORS) for 6–8 days. One serious AE (SAE) was recorded, this was a diarrhoea-related complication (sepsis) in a control subject, which resulted in hospitalisation (1.

The therapeutic mode of action of Enterosgel may occur through the adsorption of bacterial toxins known causes of diarrhoea followed by complete removal from the body.However, these studies have suffered from inherent shortcomings with regards to methodological design and reporting. Results 440 patients with IBS-D were randomised to the double-blind phase with 393 continuing to the open-label phase. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. Within a week I was down to just a few trips to the bathroom per day, which was an 85% reduction in my symptoms.